Main Article Content

Abstract

The present research is focused to formulate, optimize and evaluate a Nanostructured Lipid Carrier (NLC) containing Anti-hypertensive drug by hot homogenization technique followed by ultrasonication method, by altering formulation and process variables. Nine formulation of NLC was formulated based on formulation variable like different concentration of phospholipid and surfactant and also process variables like Homogenization time and Ultrasonication time. The objective of this research is to optimize the formulation based on Particle Size, PDI, Zeta potential, Drug content, Entrapment efficiency and to select the best formulation for in vitro studies. The particle size analysis revealed that among the nine formulations, the size of F7 formulation was found to be 10.7nm which is approximately between the ranges of (10-500 nm) of NLC. The stability of the F7 formulation was evaluated by measuring the zeta potential and polydispersity index (PDI) of the NLCs by Horiba particle size analyzer and found to be -41.2mV and 0.187 respectively, thus showing uniformity in surface charge distribution and also good dispersibility of the particles in phase and it was concluded that the F7 formulation was found to be a good and stable formulation. The percentage drug content, entrapment efficiency was found to be very high in F7 formulation viz 85.80 ± 1.64% and 89.46 ± 2.16% respectively. Thus, it was concluded that hot homogenization technique method followed by Ultrasonication was an optimized technique for the preparation of NLC nanoparticle containing Anti- Hypertensive drug like Carvedilol.                

Keywords

Nanostructured Lipid Carrier Hot Homogenization method Ultrasonication method Anti-hypertensive drug Particle size Zeta potential Polydispersity index

Article Details

How to Cite
Brito Raj S, Chandra Sekhar K.B, & Bhaskar Reddy K. (2015). Formulation, optimization and in vitro evaluation of lipid nanoparticles Containing anti-hypertensive drug . International Journal of Research in Pharmaceutical Sciences, 6(2), 127-130. Retrieved from https://pharmascope.org/ijrps/article/view/1219